Screen for 50+ cancers with a single blood test
Grade: C — Score: 55/100
The Galleri test utilizes advanced technology to detect a unique DNA 'fingerprint' of multiple cancers from a simple blood draw. This innovative approach allows for the identification of cancers that may not yet show symptoms, providing a proactive tool for early detection.
In terms of workflow, the Galleri test can be ordered annually and is designed to complement existing healthcare provider recommended screening tests. It is accessible to patients, healthcare providers, employers, and health systems, facilitating a streamlined process for cancer screening.
However, it is important to note that the Galleri test does not detect all cancers, and there is a possibility of false positive or false negative results. Therefore, it should be used in conjunction with other screening methods as advised by healthcare professionals.
Galleri Test: $949 list price
Consider switching to GRAIL: GRAIL offers similar multi-cancer early detection solutions.
Galleri's accuracy depends on the metric and study population. GRAIL's current PATHFINDER 2 intended-use materials report a 0.4% false positive rate and 61.6% positive predictive value, while current 2026 reporting describes Cancer Signal Origin accuracy as greater than 90%; sensitivity varies substantially by cancer type and stage. One current consumer product page still says around 40% of people with a Cancer Signal Detected result are expected to have cancer confirmed, so GRAIL's public positive-result expectation is not fully aligned across pages.
A Galleri Cancer Signal Detected result means the test found methylation patterns associated with cancer and reports a predicted Cancer Signal Origin to help guide follow-up. Current PATHFINDER 2-based patient and provider materials say about 61.6%, or roughly 6 in 10, people with a Cancer Signal Detected result were diagnosed with cancer after follow-up, but another current Galleri consumer page still says around 40%. The result itself is not a cancer diagnosis and requires confirmatory diagnostic evaluation.
No. GRAIL states that a No Cancer Signal Detected result does not rule out cancer because Galleri cannot detect a signal from every cancer and some cancers shed little or no DNA into the bloodstream. People should continue healthcare-provider-recommended screening and should not ignore new signs or symptoms because of a negative Galleri result.
No. GRAIL says Galleri is intended to be used in addition to, not instead of, recommended single-cancer screening such as breast, cervical, colorectal, and lung screening. Galleri does not detect all cancers, while established screening tests have evidence and guidelines specific to the cancers they target.
GRAIL recommends Galleri for adults with an elevated risk for cancer, such as people age 50 or older. GRAIL does not recommend the test for people who are pregnant, age 21 or younger, or undergoing active cancer treatment. Because Galleri is prescription-only, a licensed healthcare provider determines whether the test is appropriate for an individual patient.
GRAIL says Galleri can be taken annually and can be added to yearly wellness visits. Current GRAIL materials cite modeling and real-world analyses suggesting potential value from repeated annual screening, but this should not be read as evidence that annual Galleri screening has been proven to reduce cancer mortality. The timing of repeat testing should be discussed with the patient's healthcare provider.
Galleri has detected a shared cancer signal across more than 50 cancer types in clinical studies, including cancers without routine screening programs. Detection varies by cancer type and stage because cancers differ in how much DNA they shed into the bloodstream; GRAIL specifically notes that some cancers and early-stage disease can be harder to detect through a blood test. Galleri therefore should not be interpreted as having the same sensitivity for every cancer on its cancer-type list.
No. As of September 1, 2026, Galleri has not been cleared or approved by the U.S. Food and Drug Administration and is offered in the United States as a laboratory developed test processed by GRAIL's CLIA-certified, CAP-accredited laboratory. GRAIL submitted a Premarket Approval application on January 29, 2026, and the FDA Molecular and Clinical Genetics Panel is scheduled to review the application on September 23, 2026.
Both Galleri and Cancerguard are prescription-only blood-based multi-cancer early detection tests designed to detect signals associated with more than 50 cancer types, and neither is currently FDA cleared or approved. Galleri has a $949 list price and uses targeted methylation analysis with machine learning to detect a cancer signal and predict a Cancer Signal Origin; Cancerguard lists a $689 self-pay price and combines DNA methylation with protein biomarkers. Their published performance numbers come from different study designs and populations, so they should not be treated as a head-to-head accuracy comparison.
Galleri is a $949 prescription blood test that analyzes cell-free DNA methylation patterns for a cancer signal and predicts a Cancer Signal Origin when one is detected. Prenuvo uses radiation-free MRI rather than blood biomarkers; its current U.S. pricing is $1,199 for a Focused Scan and $2,499 for a Whole Body Scan. Both companies describe their products as additions to established screening rather than replacements for guideline-based tests, and they provide different molecular versus imaging views rather than equivalent tests.
How AI agents (ChatGPT, Perplexity, Claude, others) read this review page in the past 7 days. Updated weekly. View Galleri AI Visibility Report.